Saturday, February 01, 2020 10:33:59 AM
Soon we will get upgrade news, this will boost the price extra. I think they will upgrade the stock to $10,00 for the current year.
The current shareprice is extreme undervalued.
If they will get FDA approval than we could see share price upgrades which will be extreme higher. But I think that a big pharma will soon buy out Genprex even before the FDA decision. Either way, we will have big profits this year..
...
The current shareprice is extreme undervalued.
If they will get FDA approval than we could see share price upgrades which will be extreme higher. But I think that a big pharma will soon buy out Genprex even before the FDA decision. Either way, we will have big profits this year..
...
Recent GNPX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:05:14 PM
- Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting • PR Newswire (US) • 05/14/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:35:46 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/11/2026 09:52:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:00:55 PM
- Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer • PR Newswire (US) • 04/30/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 08:47:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 11:07:21 AM
- Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting • PR Newswire (US) • 04/28/2026 11:00:00 AM
- Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting • PR Newswire (US) • 04/22/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 11:02:55 AM
- Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy • PR Newswire (US) • 04/21/2026 11:00:00 AM
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting • PR Newswire (US) • 04/20/2026 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 08:34:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:34:58 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting • PR Newswire (US) • 03/18/2026 11:00:00 AM
- Genprex to Participate at BIO Europe Spring 2026 • PR Newswire (US) • 03/10/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 11:33:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:08:16 PM
- Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer • PR Newswire (US) • 02/23/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/10/2026 01:04:05 PM
- Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers • PR Newswire (US) • 02/10/2026 01:00:00 PM
